Acarbose in the Treatment of Type 2 Diabetes:Cost-Effectiveness Analysis / 中国药房
China Pharmacy
;
(12)2007.
Article
in Chinese
| WPRIM
| ID: wpr-532842
ABSTRACT
OBJECTIVE:
To evaluate the cost-effectiveness of Acarbose in the treatment of type 2 diabetes.METHODS:
The CORE diabetes model was employed to evaluate the long-term cost-effectiveness of Acarbose in the treatment of type 2 diabetes.RESULTS:
Acarbose treatment prolonged patients' life expectancy by 0.27 years and quality-adjusted life expectancy by 0.26 years,but its cost was 17 081 yuan higher than in the control group. The incremental cost-effectiveness ratio was 62 717 yuan per life expectancy gained and 66 633 yuan per quality-adjusted life expectancy gained. An acceptability curve of cost-effectiveness showed that 76% of the patients would regard that Acarbose is cost-effectiveness when a willingness to pay was 100 000 yuan.CONCLUSION:
Acarbose has long-term cost-effectiveness in the treatment of type 2 diabetes.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Health economic evaluation
Language:
Chinese
Journal:
China Pharmacy
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS